Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ID-LV305 · 1 trial · 3 indications
Incidence of Treatment-Emergent Adverse Events \[Safety and Tolerability\].
| Arm | Type | Description |
|---|---|---|
| ID-LV305 | EXPERIMENTAL | Dose escalation and expansion cohort including treatment of melanoma |
| Name | Type | Description |
|---|---|---|
| ID-LV305 | BIOLOGICAL | pembrolizumab |
Inclusion Criteria: * Locally advanced, relapsed, and/or metastatic cancer with low or minimal tumor burden which may or may not be measurable; no tumor size criteria are used. * Tumor histology consistent with melanoma tumor specimen positive for NY-ESO-1 expression by IHC and/or RT-PCR. * b. In P...
ID-LV305 is an investigational monoclonal antibody being studied for use in melanoma. It is currently enrolling patients with locally advanced, relapsed or metastatic cancer that expresses NY-ESO-1, including melanoma. The drug is in Phase 1 clinical development and is not yet approved by the FDA.
ID-LV305 targets NY-ESO-1, a tumor antigen expressed in certain cancers. The drug is designed to treat cancers that express this antigen, including melanoma, non-small cell lung cancer, and sarcoma. It is being studied in a Phase 1 clinical trial for its safety and efficacy.
ID-LV305 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The drug is currently in Phase 1 clinical development for the treatment of cancers expressing NY-ESO-1.
ID-LV305 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The drug is being studied in a completed Phase 1 trial for patients with locally advanced, relapsed or metastatic cancer expressing NY-ESO-1.
ID-LV305 has one completed clinical trial, NCT02122861, a Phase 1 study of intradermal LV305 in patients with locally advanced, relapsed or metastatic cancer expressing NY-ESO-1. The trial enrolled 47 participants in the United States and included patients with melanoma, non-small cell lung cancer, and sarcoma.
Yes, ID-LV305 is also known as LV305. The clinical trial NCT02122861 refers to the drug as LV305, and it is being developed by Merck & Company, Inc. for the treatment of cancers expressing NY-ESO-1.